Drug Trial Radar · NCT05917522
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Dec 7, 2023
Primary completion
Jul 2027
Study completion Jul 2029
Sponsor
- Sponsor type
- NIH
- First posted
- Jun 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18 months monitoring for safety and improvement in renal function, neurocognitive function, and a life participation patient reported outcome measure (PROM). The primary objective of the Observational Study is to test the validity of the HLA-DR/DQ mMM score as a prognostic biomarker for stratification of post-transplant alloimmune risk. Whereas the objective of the Nested RCT is to test whether a superior outcome in kidney function (primary endpoint), as well as secondary endpoints (neurocognitive function, and life participation PROM), will be achieved in patients who are transitioned from Tacrolimus (TAC) to abatacept, while maintaining efficacy (freedom from biopsy proven acute rejection).
Conditions
- Kidney Transplant
Interventions
AbataceptBiological
Injection: 125 mg/mL of a clear to slightly opalescent, colorless to pale-yellow solution in a single-dose prefilled ClickJect autoinjector
Standard of Care at US Transplant CentersProcedure
Control group, remaining on SOC (Tacrolimus/ Mycophenolic Acid (MPA)/ Prednisone (Pred))
Primary outcomes
What the sponsor says the trial is designed to measure.
- In the Observational Study - The occurrence of any alloimmune eventTime frame: Up to 24 months post-Kidney Transplant
- In the Nested Randomized Control Trial (RCT) - Renal function, measured as the difference in eGFRCKD-EPI at 24-months between groups (adjusted for renal function at randomization).Time frame: At 18 months post-randomization (24 months post-transplant)
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama School of Medicine: Transplantation
Birmingham, Alabama · Recruiting
Cedars Sinai Medical Center: Transplantation
Los Angeles, California · Recruiting
Ronald Reagan UCLA Medical Center: Transplantation
Los Angeles, California · Recruiting
Yale University, School of Medicine: Transplantation
New Haven, Connecticut · Recruiting
Johns Hopkins Hospital:Transplantation
Baltimore, Maryland · Recruiting
Massachusetts General Hospital: Transplantation
Boston, Massachusetts · Recruiting
Mayo Clinic Rochester: Transplantation
Rochester, Minnesota · Recruiting
Washington University School of Medicine in St. Louis
St Louis, Missouri · Recruiting
University of Nebraska Medical Center: Transplantation
Omaha, Nebraska · Recruiting
Duke University Medical Center: Transplantation
Durham, North Carolina · Recruiting
Cleveland Clinic Foundation: Transplantation
Cleveland, Ohio · Not yet recruiting
University of Pennsylvania Medical Center: Transplantation
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center: Transplantation
Pittsburgh, Pennsylvania · Recruiting
University of Virginia Health System: Transplantation
Charlottesville, Virginia · Recruiting
University of Wisconsin School of Medicine and Public Health: Transplantation
Madison, Wisconsin · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.